SEC Form 4/A · accession 0000899243-18-029164
CytoDyn Inc. · CYDY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Anthony Caracciolo
Officer — Executive Chairman · Director
Period of report
Jun 19, 2017
Accepted (ET)
Nov 16, 2018 · 5:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175680
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantsF1,F2 | $1.35 | Jun 19, 2017 | D | 333,333 | D | May 31, 2017 | May 31, 2022 | Common Stock | 333,333 | 0 | I |
Explanation of responses
- F1This report is being filed to correct certain inadvertent errors, to report (i) the warrant issued May 31, 2017 as disposed of (and not acquired) in the transaction, in Column 5, and (ii) the number of such derivative securities beneficially owned following the transaction as zero (and not 333,333), in Column 9.
- F2As part of a private offering to accredited investors, on May 31, 2017, the reporting person purchased from the issuer for a combined price of $1.0 million (i) a $1.0 million convertible promissory note, bearing interest at 7.0% annually, which is convertible into shares of the issuer's common stock at an initial conversion price of $0.75 per share, and (ii) a warrant covering 25% of the number of shares underlying the convertible promissory note, with an exercise price of $1.35 per share. Effective June 19, 2017, the issuer amended the terms of the offering to increase the warrant coverage from 25% to 50% and to decrease the warrant exercise price from $1.35 to $1.00.